- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1534-6277
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers ; volume:17 ; number:3 ; day:4 ; month:3 ; year:2016 ; pages:1-14 ; date:3.2016
Current treatment options in oncology ; 17, Heft 3 (4.3.2016), 1-14, 3.2016
- Urheber
-
El-Taji, Omar M. S.
- Beteiligte Personen und Organisationen
-
Alam, Sameer
Hussain, Syed A.
SpringerLink (Online service)
- DOI
-
10.1007/s11864-016-0390-8
- URN
-
urn:nbn:de:1111-201603075222
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- El-Taji, Omar M. S.
- Alam, Sameer
- Hussain, Syed A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Proteomics research on muscle-invasive bladder transitional cell carcinoma
The natural history of secondary muscle-invasive bladder cancer
Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival
Stromal proteome expression profile and muscle-invasive bladder cancer research
Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer
Cross-species oncogenomics offers insight into human muscle-invasive bladder cancer
Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer
Alternative splicing patterns reveal prognostic indicator in muscle-invasive bladder cancer
Dynamic changes of quality of life in muscle-invasive bladder cancer survivors
Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Proteomics research on muscle-invasive bladder transitional cell carcinoma
The natural history of secondary muscle-invasive bladder cancer
Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival
Stromal proteome expression profile and muscle-invasive bladder cancer research
Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer
Cross-species oncogenomics offers insight into human muscle-invasive bladder cancer
Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer
Alternative splicing patterns reveal prognostic indicator in muscle-invasive bladder cancer
Dynamic changes of quality of life in muscle-invasive bladder cancer survivors
Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Proteomics research on muscle-invasive bladder transitional cell carcinoma
The natural history of secondary muscle-invasive bladder cancer
Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival
Stromal proteome expression profile and muscle-invasive bladder cancer research
Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer
Cross-species oncogenomics offers insight into human muscle-invasive bladder cancer
Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer
Alternative splicing patterns reveal prognostic indicator in muscle-invasive bladder cancer
Dynamic changes of quality of life in muscle-invasive bladder cancer survivors